FI924193A0 - Heterovesikulaera liposomer. - Google Patents

Heterovesikulaera liposomer.

Info

Publication number
FI924193A0
FI924193A0 FI924193A FI924193A FI924193A0 FI 924193 A0 FI924193 A0 FI 924193A0 FI 924193 A FI924193 A FI 924193A FI 924193 A FI924193 A FI 924193A FI 924193 A0 FI924193 A0 FI 924193A0
Authority
FI
Finland
Prior art keywords
emulsion
vial
composition
addition
liposomer
Prior art date
Application number
FI924193A
Other languages
English (en)
Other versions
FI924193A (fi
FI104464B (fi
Inventor
Kim Sinil
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of FI924193A publication Critical patent/FI924193A/fi
Publication of FI924193A0 publication Critical patent/FI924193A0/fi
Application granted granted Critical
Publication of FI104464B publication Critical patent/FI104464B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
FI924193A 1990-03-21 1992-09-18 Menetelmä heterovesikulaariliposomien valmistamiseksi FI104464B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49684690A 1990-03-21 1990-03-21
US49684690 1990-03-21
US9101849 1991-03-20
PCT/US1991/001849 WO1991014445A1 (en) 1990-03-21 1991-03-20 Heterovesicular liposomes

Publications (3)

Publication Number Publication Date
FI924193A FI924193A (fi) 1992-09-18
FI924193A0 true FI924193A0 (fi) 1992-09-18
FI104464B FI104464B (fi) 2000-02-15

Family

ID=23974416

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924193A FI104464B (fi) 1990-03-21 1992-09-18 Menetelmä heterovesikulaariliposomien valmistamiseksi

Country Status (20)

Country Link
EP (1) EP0524968B1 (fi)
JP (1) JP3461000B2 (fi)
KR (1) KR100203223B1 (fi)
CN (1) CN1053101C (fi)
AT (1) ATE123412T1 (fi)
AU (1) AU655177B2 (fi)
CA (1) CA2078666C (fi)
DE (1) DE69110281T2 (fi)
DK (1) DK0524968T3 (fi)
ES (1) ES2073164T3 (fi)
FI (1) FI104464B (fi)
IE (1) IE62772B1 (fi)
IL (1) IL97615A (fi)
NO (1) NO304576B1 (fi)
NZ (1) NZ237464A (fi)
PT (1) PT97101B (fi)
RU (1) RU2120795C1 (fi)
SA (1) SA93130496B1 (fi)
WO (1) WO1991014445A1 (fi)
ZA (1) ZA911974B (fi)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3278273B2 (ja) * 1993-12-17 2002-04-30 キヤノン株式会社 薬剤徐放性カプセル
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP1365028B1 (en) 1996-12-13 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Method for expression of PDGF or IGF proteins in yeast
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
EP2198854B1 (en) 1997-09-18 2011-11-30 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
JP4472866B2 (ja) 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
ES2384094T3 (es) 1997-11-14 2012-06-29 Pacira Pharmaceuticals, Inc. Producción de liposomas multivesiculares
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
AU1316200A (en) 1998-10-15 2000-05-01 Chiron Corporation Metastatic breast and colon cancer regulated genes
ES2310055T3 (es) 1998-12-16 2008-12-16 Novartis Vaccines & Diagnostic Quinasa humana dependiente de ciclina (hpnqalre).
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ.ピー.アー. 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
AU784518B2 (en) 2000-01-17 2006-04-27 Glaxosmithkline Biologicals S.A. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2001096523A2 (en) 2000-06-15 2001-12-20 Chiron Corporation Polynucleotides related to colon cancer
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
ES2397627T3 (es) 2000-12-07 2013-03-08 Novartis Vaccines And Diagnostics, Inc. Retrovirus endógenos regulados por aumento en el cáncer de próstata
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US7309783B2 (en) 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
KR20030022094A (ko) 2001-05-24 2003-03-15 (주)휴먼디엔에이테크놀로지 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
RU2316591C2 (ru) 2001-11-09 2008-02-10 Джорджтаун Юниверсити Новые изоформы ингибитора роста васкулярных эндотелиальных клеток
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
CA2472282A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
AU2003218350A1 (en) 2002-03-21 2003-10-08 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
CA2489292A1 (en) 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004074321A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
PL379983A1 (pl) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
KR20070001932A (ko) 2003-12-23 2007-01-04 리나트 뉴로사이언스 코퍼레이션 작용물질 항 티알케이씨 항체 및 그의 사용 방법
CA2561696C (en) 2004-03-29 2013-09-03 Galpharma Co., Ltd. Novel modified galectin 9 proteins and use thereof
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
WO2006085979A2 (en) 2004-07-09 2006-08-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus g glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1781704A2 (en) 2004-07-30 2007-05-09 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
DE05852057T1 (de) 2004-11-23 2007-11-29 Neuromolecular Pharmaceuticals Inc., Emeryville Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
JP2008535494A (ja) 2005-04-07 2008-09-04 サグレシュ ディスカバリー, インコーポレイテッド 癌関連遺伝子(prlr)
EP1865981A2 (en) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in cancer diagnosis, detection and treatment
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
BRPI0613770A2 (pt) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anticorpos anti-cd26 e métodos de uso destes
PL2380592T3 (pl) 2005-11-14 2018-07-31 Teva Pharmaceuticals International Gmbh Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
JP5313886B2 (ja) 2006-06-07 2013-10-09 バイオアライアンス セー.フェー. 癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
EP2134365B1 (en) 2007-03-21 2019-03-13 Effat Emamian Compositions and methods for inhibiting tumor cell growth
WO2008124176A2 (en) 2007-04-10 2008-10-16 The Administrators Of The Tulane Educational Fund Soluble and membrane-anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP3587450A1 (en) 2007-12-17 2020-01-01 Pfizer Limited Treatment of interstitial cystitis with ngf inhibitors
NZ585959A (en) 2007-12-18 2012-09-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
CA3154626A1 (en) 2009-04-14 2010-10-21 Glaxosmithkline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CA2767536A1 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
JP2012532626A (ja) 2009-07-16 2012-12-20 ノバルティス アーゲー 無毒化されたEscherichiacoli免疫原
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ, インコーポレイテッド アマンタジン組成物および使用方法
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
SG10201507722QA (en) 2010-03-11 2015-10-29 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
JP5936702B2 (ja) 2011-11-11 2016-06-22 ライナット ニューロサイエンス コーポレイション Trop−2に対して特異的な抗体およびこれらの使用
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US9249224B2 (en) 2011-12-22 2016-02-02 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
AU2013286866B2 (en) 2012-07-02 2018-03-01 Commonwealth Scientific And Industrial Research Organization Paramyxovirus and methods of use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
CN105051068A (zh) 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
TWI736515B (zh) 2013-11-13 2021-08-21 美商輝瑞大藥廠 類腫瘤壞死因子之配體1a之專一性抗體及其組合物及用途
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
LT3119431T (lt) 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
AU2016248946B2 (en) 2015-04-13 2022-03-10 Pfizer Inc. Therapeutic antibodies and their uses
CN108137705B (zh) 2015-07-21 2022-11-08 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CN107922506B (zh) 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
SI3350220T1 (sl) 2015-09-15 2021-12-31 Scholar Rock, Inc. Protitelesa proti pro/latentnemu miostatinu in uporabe le-teh
JP6661319B2 (ja) * 2015-09-28 2020-03-11 小林製薬株式会社 リポソーム
CA2946113A1 (en) 2015-10-23 2017-04-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
EP3589657A1 (en) 2017-03-03 2020-01-08 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
MX2019014465A (es) 2017-06-02 2020-01-23 Pfizer Anticuerpos especificos para flt3 y sus usos.
EP3639170B1 (en) 2017-06-13 2021-03-24 BostonGene Corporation Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
CN110997002A (zh) 2017-07-13 2020-04-10 麻省理工学院 靶向hdac2-sp3复合体以增强突触功能
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
EP4414034A2 (en) 2018-05-23 2024-08-14 Pfizer Inc. Antibodies specific for cd3 and uses thereof
KR102584675B1 (ko) 2018-05-23 2023-10-05 화이자 인코포레이티드 GUCY2c에 특이적인 항체 및 이의 용도
CA3146077A1 (en) 2019-07-03 2021-02-18 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
KR20230117327A (ko) 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
US20240029829A1 (en) 2020-12-04 2024-01-25 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4330969A1 (en) 2021-04-29 2024-03-06 BostonGene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
CH624011A5 (fi) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes

Also Published As

Publication number Publication date
FI924193A (fi) 1992-09-18
CN1055663A (zh) 1991-10-30
RU2120795C1 (ru) 1998-10-27
IL97615A0 (en) 1992-06-21
CN1053101C (zh) 2000-06-07
NZ237464A (en) 1995-02-24
NO923624D0 (no) 1992-09-17
DE69110281T2 (de) 1995-11-09
AU7580691A (en) 1991-10-21
ZA911974B (en) 1994-08-22
EP0524968A1 (en) 1993-02-03
JPH05507680A (ja) 1993-11-04
AU655177B2 (en) 1994-12-08
DK0524968T3 (da) 1995-07-31
ES2073164T3 (es) 1995-08-01
IE910911A1 (en) 1991-09-25
CA2078666A1 (en) 1991-09-22
WO1991014445A1 (en) 1991-10-03
DE69110281D1 (de) 1995-07-13
ATE123412T1 (de) 1995-06-15
JP3461000B2 (ja) 2003-10-27
IE62772B1 (en) 1995-02-22
KR100203223B1 (ko) 1999-06-15
EP0524968A4 (en) 1993-03-24
IL97615A (en) 1995-06-29
NO304576B1 (no) 1999-01-18
PT97101A (pt) 1991-11-29
EP0524968B1 (en) 1995-06-07
SA93130496B1 (ar) 2004-08-14
FI104464B (fi) 2000-02-15
CA2078666C (en) 2001-10-02
NO923624L (no) 1992-09-17
PT97101B (pt) 1998-08-31

Similar Documents

Publication Publication Date Title
ES2073164T3 (es) Liposomas heterovesiculares.
FI922151A0 (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
FR2680512B1 (fr) Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
DE3577851D1 (de) Inositoltriphosphat, verfahren zu seiner herstellung und dieses enthaltende zubereitung.
SE8103843L (sv) Farmaceutisk mixtur
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
DE3166084D1 (en) Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
SE8102456L (sv) Farmaceutisk komposition for oral administering och innehallande cytidindifosfokolin
ES2041617T3 (es) Productos intermedios para agentes de quelacion con simetria prefijada y procedimiento para su preparacion.
HU900753D0 (en) Process for preparation of phenylhydrazones and for pharmaceutical compositions containing them
DK243280A (da) 3,4,5-trihydroxypiperidinderivater deres fremstilling og anvendelse
SE8302580L (sv) Substituerade iminoderivat av dihydrobensopyran och dihydrobensotiopyran och forfarande for deras framstellning
JPS56138174A (en) Phenylpiperazine derivative of 1,3,4-oxadiazolylphenol, manufacture and medicine containing same
EP0026369A3 (en) Carbamates, their preparation and pharmaceutical compositions containing them
IL82925A0 (en) Tetrahydrobenzothiazoles,their preparation and pharmaceutical compositions containing them
SE8503447L (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
FR2595703B1 (fr) Nouveaux phospholipides, leur procede et les intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
PT72247A (fr) Procede de preparation de nouveaux derives de l'amino-1 propanol-2 et leur application en therapeutique

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: DEPOTECH CORPORATION